Lucid Capital Markets initiates Adial Pharmaceuticals stock with buy rating on colitis drug potential

Lucid Capital Markets initiates Adial Pharmaceuticals stock with buy rating on colitis drug potential

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.